title: [Anticoagulant therapy with recombinant hirudin in patients with thrombopenia induced by heparin].
abstract: OBJECTIVE
  Heparin-induced thrombocytopenia is an uncommon and severe complication of heparin therapy. Both venous and arterial thromboembolic events can occur, requiring withdrawal of the heparin therapy. When anticoagulant therapy is mandatory, recombinant hirudin can be used.
  
  
  METHODS
  We used recombinant hirudin (HBW 023) in 6 patients with heparin induced thrombocytopenia. In case of venous thromboembolism, an initial intravenous bolus (0.07 mg/kg) was followed by continuous infusion (0.05 mg/kg/h); for arterial thromboembolism the initial bolus was 0.7 mg/kg and infusion rate 0.15 mg/kg/h. When possible oral anticoagulants were started and hirudin withdrawn when the INR ratio reached 3.
  
  
  RESULTS
  The clinical course was uneventful in all 6 patients. There was no recurrent thromboembolism. Cephalin-activated coagulation time (patient/control) varied between 1.8 and 3.5 (median 2.4) during hirudin administration. Platelet count rose to the nadir (median 70 x 10(9)/l, range 15-90) reaching over 100 x 10(9)/l in all patients between the third and sixth day (median 5 days) after stopping heparin.
  
  
  CONCLUSIONS
  Intravenous administration of hirudin provides effective immediate anticoagulation in patients with heparin-induced thrombocytopenia, thus allowing conversion to oral anticoagulants without risking recurrent thromboembolism.
authors.affiliation: Service de Cardiologie, Centre Hospitalier Saint-Jacques, Besançon.
authors.forename: F
authors.initials: F
authors.lastname: Schiele
authors.forename: A
authors.initials: A
authors.lastname: Vuillemenot
authors.forename: T
authors.initials: T
authors.lastname: Mouhat
authors.forename: Y
authors.initials: Y
authors.lastname: Kieffer
authors.forename: T
authors.initials: T
authors.lastname: Anguenot
authors.forename: Y
authors.initials: Y
authors.lastname: Bernard
authors.forename: J P
authors.initials: JP
authors.lastname: Bassand
mesh_terms: D000368:Aged; D000991:Antithrombins / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006493:Heparin / Q000009:adverse effects*; D024764:Hirudin Therapy; D006629:Hirudins / Q000009:adverse effects; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced*
chemical_list: D000991:Antithrombins; D006629:Hirudins; D011994:Recombinant Proteins; D006493:Heparin; C083544:lepirudin
vernacular_title: Traitement anti-thrombique par hirudine recombinante chez des patients ayant une thrombopénie induite par l'héparine.